{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:50:46Z","timestamp":1785426646330,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,5,4]],"date-time":"2014-05-04T00:00:00Z","timestamp":1399161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00432-014-1689-0","type":"journal-article","created":{"date-parts":[[2014,5,3]],"date-time":"2014-05-03T12:20:51Z","timestamp":1399119651000},"page":"1283-1293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation"],"prefix":"10.1007","volume":"140","author":[{"given":"Lukas","family":"Peiffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Jonas","family":"Poll-Wolbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Flamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Gehrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Anton","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,4]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1128\/MCB.20.18.6882-6890.2000","volume":"20","author":"AN Billin","year":"2000","unstructured":"Billin AN, Thirlwell H, Ayer DE (2000) Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol 20:6882\u20136890","journal-title":"Mol Cell Biol"},{"key":"1689_CR2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769\u2013784. doi: 10.1038\/nrd2133","journal-title":"Nat Rev Drug Discov"},{"key":"1689_CR3","doi-asserted-by":"crossref","first-page":"R943","DOI":"10.1016\/j.cub.2008.08.017","volume":"18","author":"KM Cadigan","year":"2008","unstructured":"Cadigan KM (2008) Wnt-beta-catenin signaling. Curr Biol 18:R943\u2013R947. doi: 10.1016\/j.cub.2008.08.017","journal-title":"Curr Biol"},{"key":"1689_CR4","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1101\/gad.11.24.3286","volume":"11","author":"KM Cadigan","year":"1997","unstructured":"Cadigan KM, Nusse R (1997) Wnt signaling: a common theme in animal development. Genes Dev 11:3286\u20133305","journal-title":"Genes Dev"},{"key":"1689_CR5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","volume":"370","author":"AJM Ruijter De","year":"2003","unstructured":"De Ruijter AJM, van Gennip AH, Caron HN et al (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737\u2013749. doi: 10.1042\/BJ20021321","journal-title":"Biochem J"},{"key":"1689_CR6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","volume":"371","author":"G Dighiero","year":"2008","unstructured":"Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet 371:1017\u20131029. doi: 10.1016\/S0140-6736(08)60456-0","journal-title":"Lancet"},{"key":"1689_CR7","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","volume":"85","author":"H D\u00f6hner","year":"1995","unstructured":"D\u00f6hner H, Fischer K, Bentz M et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580\u20131589","journal-title":"Blood"},{"key":"1689_CR8","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910\u20131916. doi: 10.1056\/NEJM200012283432602","journal-title":"N Engl J Med"},{"key":"1689_CR9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31\u201339. doi: 10.1182\/blood-2006-06-025999","journal-title":"Blood"},{"key":"1689_CR10","doi-asserted-by":"crossref","unstructured":"Eichhorst B, Dreyling M, Robak T, et al (2011) Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22:vi50\u2013vi54. doi: 10.1093\/annonc\/mdr377","DOI":"10.1093\/annonc\/mdr377"},{"key":"1689_CR11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1600-0609.2010.01494.x","volume":"85","author":"A Filipovich","year":"2010","unstructured":"Filipovich A, Gandhirajan RK, Gehrke I et al (2010) Evidence for non-functional Dickkopf-1 (DKK-1) signaling in chronic lymphocytic leukemia (CLL). Eur J Haematol 85:309\u2013313. doi: 10.1111\/j.1600-0609.2010.01494.x","journal-title":"Eur J Haematol"},{"key":"1689_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1188\/12.CJON.195-204","volume":"16","author":"R Frye","year":"2012","unstructured":"Frye R, Myers M, Axelrod KC et al (2012) Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs 16:195\u2013204. doi: 10.1188\/12.CJON.195-204","journal-title":"Clin J Oncol Nurs"},{"key":"1689_CR13","first-page":"971","volume":"2","author":"L Fuino","year":"2003","unstructured":"Fuino L, Bali P, Wittmann S et al (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971\u2013984","journal-title":"Mol Cancer Ther"},{"key":"1689_CR14","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","volume":"29","author":"D Gonzalez","year":"2011","unstructured":"Gonzalez D, Martinez P, Wade R et al (2011) Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 29:2223\u20132229. doi: 10.1200\/JCO.2010.32.0838","journal-title":"J Clin Oncol"},{"key":"1689_CR15","author":"M Hallek","year":"2013","unstructured":"Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. doi: 10.1002\/ajh.23491","journal-title":"Am J Hematol"},{"key":"1689_CR16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/dna.2011.1314","volume":"31","author":"M Isin","year":"2012","unstructured":"Isin M, Yenerel M, Aktan M et al (2012) Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia. DNA Cell Biol 31:777\u2013782. doi: 10.1089\/dna.2011.1314","journal-title":"DNA Cell Biol"},{"key":"1689_CR17","doi-asserted-by":"crossref","unstructured":"Iwamoto M, Friedman EJ, Sandhu P, et al Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol 1\u201316. doi: 10.1007\/s00280-013-2220-z","DOI":"10.1007\/s00280-013-2220-z"},{"key":"1689_CR18","first-page":"7291","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS, Blake M, Baek JH et al (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291\u20137300","journal-title":"Cancer Res"},{"key":"1689_CR19","author":"W Lento","year":"2013","unstructured":"Lento W, Congdon K, Voermans C et al (2013) Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol. doi: 10.1101\/cshperspect.a008011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1689_CR20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/med.20056","volume":"26","author":"H-Y Lin","year":"2006","unstructured":"Lin H-Y, Chen C-S, Lin S-P et al (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26:397\u2013413. doi: 10.1002\/med.20056","journal-title":"Med Res Rev"},{"key":"1689_CR21","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1073\/pnas.0308648100","volume":"101","author":"D Lu","year":"2004","unstructured":"Lu D, Zhao Y, Tawatao R et al (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 101:3118\u20133123. doi: 10.1073\/pnas.0308648100","journal-title":"Proc Natl Acad Sci USA"},{"key":"1689_CR22","doi-asserted-by":"crossref","first-page":"e8294","DOI":"10.1371\/journal.pone.0008294","volume":"4","author":"D Lu","year":"2009","unstructured":"Lu D, Liu JX, Endo T et al (2009) Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt\/beta-catenin pathway. PLoS ONE 4:e8294. doi: 10.1371\/journal.pone.0008294","journal-title":"PLoS ONE"},{"key":"1689_CR23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/35077108","volume":"411","author":"B Mao","year":"2001","unstructured":"Mao B, Wu W, Li Y et al (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321\u2013325. doi: 10.1038\/35077108","journal-title":"Nature"},{"key":"1689_CR24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","volume":"25","author":"PA Marks","year":"2007","unstructured":"Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotech 25:84\u201390. doi: 10.1038\/nbt1272","journal-title":"Nat Biotech"},{"key":"1689_CR25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/joim.1997.242.s740.63","volume":"740","author":"E Montserrat","year":"1997","unstructured":"Montserrat E, Bosch F, Rozman C (1997) Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectives. J Intern Med Suppl 740:63\u201367","journal-title":"J Intern Med Suppl"},{"key":"1689_CR26","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood-2005-02-0819","volume":"107","author":"E Montserrat","year":"2006","unstructured":"Montserrat E, Moreno C, Esteve J et al (2006) How I treat refractory CLL. Blood 107:1276\u20131283. doi: 10.1182\/blood-2005-02-0819","journal-title":"Blood"},{"key":"1689_CR27","doi-asserted-by":"crossref","unstructured":"Pinilla-Ibarz J, McQuary A (2010) Chronic lymphocytic leukemia: putting new treatment options into perspective. Cancer Control 17:4\u201315; quiz 16","DOI":"10.1177\/1073274810017002S03"},{"key":"1689_CR28","author":"P Polakis","year":"2012","unstructured":"Polakis P (2012) Wnt signaling in cancer. Cold Spring Harb Perspect Biol. doi: 10.1101\/cshperspect.a008052","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1689_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.20200","volume":"32","author":"E Pontiki","year":"2012","unstructured":"Pontiki E, Hadjipavlou-Litina D (2012) Histone deacetylase inhibitors (HDACIs). Structure\u2013activity relationships: history and new QSAR perspectives. Med Res Rev 32:1\u2013165. doi: 10.1002\/med.20200","journal-title":"Med Res Rev"},{"key":"1689_CR30","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.leu.2402531","volume":"16","author":"T Robak","year":"2002","unstructured":"Robak T, Kasznicki M (2002) Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 16:1015\u20131027. doi: 10.1038\/sj.leu.2402531","journal-title":"Leukemia"},{"key":"1689_CR31","first-page":"409","volume":"2","author":"PJ Shami","year":"2003","unstructured":"Shami PJ, Saavedra JE, Wang LY et al (2003) JS-K, a glutathione\/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther 2:409\u2013417","journal-title":"Mol Cancer Ther"},{"key":"1689_CR32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11\u201330. doi: 10.3322\/caac.21166","journal-title":"CA Cancer J Clin"},{"key":"1689_CR33","doi-asserted-by":"crossref","first-page":"596","DOI":"10.18632\/oncotarget.194","volume":"1","author":"S Sikandar","year":"2010","unstructured":"Sikandar S, Dizon D, Shen X et al (2010) The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 1:596\u2013605","journal-title":"Oncotarget"},{"key":"1689_CR34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/CS20120504","volume":"124","author":"J Tang","year":"2013","unstructured":"Tang J, Yan H, Zhuang S (2013) Histone deacetylases as targets for treatment of multiple diseases. Clin Sci 124:651\u2013662. doi: 10.1042\/CS20120504","journal-title":"Clin Sci"},{"key":"1689_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7164\/antibiotics.29.1","volume":"29","author":"N Tsuji","year":"1976","unstructured":"Tsuji N, Kobayashi M, Nagashima K et al (1976) A new antifungal antibiotic, trichostatin. J Antibiot 29:1\u20136","journal-title":"J Antibiot"},{"key":"1689_CR36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10428190601059829","volume":"48","author":"B Turgut","year":"2007","unstructured":"Turgut B, Vural O, Pala FS et al (2007) 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma 48:311\u2013320. doi: 10.1080\/10428190601059829","journal-title":"Leuk Lymphoma"},{"key":"1689_CR37","first-page":"971","volume":"7","author":"DM Vigushin","year":"2001","unstructured":"Vigushin DM, Ali S, Pace PE et al (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7:971\u2013976","journal-title":"Clin Cancer Res"},{"key":"1689_CR38","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","volume":"265","author":"M Yoshida","year":"1990","unstructured":"Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174\u201317179","journal-title":"J Biol Chem"},{"key":"1689_CR39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/bies.950170510","volume":"17","author":"M Yoshida","year":"1995","unstructured":"Yoshida M, Horinouchi S, Beppu T (1995) Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 17:423\u2013430. doi: 10.1002\/bies.950170510","journal-title":"BioEssays"},{"key":"1689_CR40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2011.02.002","volume":"25","author":"T Zenz","year":"2011","unstructured":"Zenz T, Mertens D, D\u00f6hner H, Stilgenbauer S (2011) Importance of genetics in chronic lymphocytic leukemia. Blood Rev 25:131\u2013137. doi: 10.1016\/j.blre.2011.02.002","journal-title":"Blood Rev"},{"key":"1689_CR41","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1182\/blood-2011-11-312421","volume":"119","author":"T Zenz","year":"2012","unstructured":"Zenz T, Gribben JG, Hallek M et al (2012) Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 119:4101\u20134107. doi: 10.1182\/blood-2011-11-312421","journal-title":"Blood"},{"key":"1689_CR42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","volume":"125","author":"C Zhang","year":"2005","unstructured":"Zhang C, Richon V, Ni X et al (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045\u20131052. doi: 10.1111\/j.0022-202X.2005.23925.x","journal-title":"J Invest Dermatol"},{"key":"1689_CR43","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0702136104","volume":"104","author":"Q Zhang","year":"2007","unstructured":"Zhang Q, Major MB, Takanashi S et al (2007) Small-molecule synergist of the Wnt\/beta-catenin signaling pathway. Proc Natl Acad Sci USA 104:7444\u20137448. doi: 10.1073\/pnas.0702136104","journal-title":"Proc Natl Acad Sci USA"},{"key":"1689_CR44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2741\/e86","volume":"2","author":"L Zhao","year":"2010","unstructured":"Zhao L, Au JL-S, Wientjes MG (2010) Comparison of methods for evaluating drug\u2013drug interaction. Front Biosci (Elite Ed) 2:241\u2013249","journal-title":"Front Biosci (Elite Ed)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1689-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-014-1689-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1689-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T18:50:29Z","timestamp":1648925429000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-014-1689-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,4]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s00432-014-1689-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,4]]}}}